Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combretastatin A1 phosphate - Oncotelic Therapeutics

X
Drug Profile

Combretastatin A1 phosphate - Oncotelic Therapeutics

Alternative Names: CA1; CA1P; Combrestatin A1 diphosphate; Combretastatin A1 di-phosphate; OXi 4503

Latest Information Update: 17 May 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arizona State University
  • Developer Mateon Therapeutics; Oncotelic Therapeutics
  • Class Antineoplastics; Combretastatins; Diphosphates; Stilbenes
  • Mechanism of Action Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No
  • Available For Licensing Yes - Acute myeloid leukaemia

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Liver cancer; Liver metastases; Myelodysplastic syndromes
  • No development reported Solid tumours

Most Recent Events

  • 11 May 2022 Oncotelic Therapeutics has patent protection for Oxi4503 in USA
  • 20 Apr 2022 Oncotelic Therapeutics has patent protection for combretastatin A1 phosphate in the US
  • 15 Apr 2021 Phase I/II development for Acute myeloid leukaemia and Myelodysplastic syndromes is still underway in USA (Mateon Therapeutics pipeline, April 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top